RT Journal Article
SR Electronic
T1 Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.25.20238592
DO 10.1101/2020.11.25.20238592
A1 Cagigi, Alberto
A1 Yu, Meng
A1 Falck-Jones, Sara
A1 Vangeti, Sindhu
A1 Österberg, Björn
A1 Åhlberg, Eric
A1 Azizmohammadi, Lida
A1 Falck-Jones, Ryan
A1 Gubisch, Pia C
A1 Ödemis, Mert
A1 Ghafoor, Farangies
A1 Svensson, Julia
A1 Eisele, Mona
A1 Lenart, Klara
A1 Bell, Max
A1 Johansson, Niclas
A1 Albert, Jan
A1 Sälde, Jörgen
A1 Pettie, Deleah
A1 Murphy, Michael
A1 Carter, Lauren
A1 King, Neil P
A1 Ols, Sebastian
A1 Färnert, Anna
A1 Loré, Karin
A1 Smed-Sörensen, Anna
YR 2021
UL http://medrxiv.org/content/early/2021/05/20/2020.11.25.20238592.abstract
AB Understanding the presence and durability of antibodies against SARS-CoV-2 in the airways is required to provide insights on the ability of individuals to neutralize the virus locally and prevent viral spread. Here, we longitudinally assessed both systemic and airway immune responses upon SARS-CoV-2 infection in a clinically well-characterized cohort of 147 infected individuals representing the full spectrum of COVID-19 severity; from asymptomatic infection to fatal disease. In addition, we evaluated how SARS-CoV-2 vaccination influenced the antibody responses in a subset of these individuals during convalescence. Not only systemic but also airway antibody responses correlated with the degree of disease severity with increasing levels in patients with mild, moderate and severe disease, respectively. However, while systemic IgG levels were durable for up to 8 months, airway IgG and IgA had declined significantly within 3 months. In contrast, antigen-specific memory B cells were well maintained and comparable across disease severity. After vaccination, there was an increase in both systemic and airway antibodies, in particular IgG, often exceeding the levels found during acute disease. In contrast to plasma, airway antibody levels were significantly elevated after the boost vaccination, highlighting the importance of prime and boost vaccination also for previously infected individuals to obtain optimal mucosal protection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill & Melinda Gates Foundation, the Knut and Alice Wallenberg Foundation through SciLifeLab and Karolinska Institutet.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority, and performed according to the Declaration of Helsinki. Reference: 2015/1949-31/4All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings os this study are available from the corresponding author on reasonable request.